B-cell precursor ALL: inotuzumab ozogamicin tops standard therapy

  • Kantarjian HM & al.
  • Cancer
  • 28 Mar 2019

  • curated by David Reilly
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (R/R BCP ALL), inotuzumab ozogamicin (InO) delivered superior rates of complete remission (CR)/CR with incomplete hematological recovery (CRi) vs standard-of-care (SOC) intensive chemotherapy.

Why this matters

  • 5-year OS in this setting is approximately 5%-10%; a significant unmet need therefore persists for an improved treatment option.

Study design

  • Final report at >2 years of follow-up from the phase 3 INO-VATE study of InO (n=164) vs SOC (n=162) in 326 patients with R/R BCP ALL.
  • Funding: Pfizer, Inc.

Key results

  • 73.8% of patients achieved CR/CRi with InO vs 35.0% with SOC; the CR/CRi benefit with InO was consistent across all patient subgroups.
  • Median OS: 7.7 (95% CI, 6.0-9.2) months with InO vs 6.2 (95% CI, 4.7-8.3) months with SOC.
  • 39.6% (95% CI, 32.1%-47.6%) of patients in the InO group vs 10.5% (95% CI, 6.2%-16.3%) in the SOC group proceeded to hematopoietic stem cell transplant after achieving CR/CRi before initiating follow-up induction therapy (P<.0001>
  • The most frequent all-grade and grade ≥3 adverse events were hematologic in both treatment groups.

Limitations

  • Limited number of patients with t(4;11) karyotype.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit